Pulmonary microvessel density is a marker of angiogenesis in children after cavopulmonary anastomosis  by Starnes, Sandra L. et al.
902
Pulmonary arteriovenous malformations (PAVMs) area cause of progressive cyanosis in children after
cavopulmonary anastomosis. The development of
PAVMs in these children may be due to the absence of a
hepatic inhibitor of angiogenesis in the pulmonary circu-
lation when pulmonary blood flow is derived exclusively
from the superior vena cava and is devoid of hepatic
venous effluent.1-3 Supporting the concept that this is an
angiogenically active lesion, we4 have demonstrated
greatly increased numbers of blood vessels that extend
far into the periphery of the lung in children with clini-
cally symptomatic PAVMs after cavopulmonary anasto-
mosis. However, if this phenomenon is due to the pres-
Objective: Pulmonary arteriovenous malformations cause progressive
cyanosis in children after cavopulmonary anastomosis and may be due to
abnormal angiogenesis. We determined the microvessel density, a marker of
angiogenesis, in the lungs of children after cavopulmonary anastomosis. 
Methods: Lung biopsy specimens were obtained from 8 children after
cavopulmonary anastomosis and from 4 control patients. Three of the 8 chil-
dren undergoing cavopulmonary anastomosis had clinical and angiographic
evidence of pulmonary arteriovenous malformations, whereas the other 5
were free of symptoms. Routine histologic and immunohistologic stains
were performed with a primary antibody to von Willebrand factor.
Microvessel staining for von Willebrand factor was determined for 10 fields
(200×) per patient.
Results: Patients with and without pulmonary arteriovenous malformations
after cavopulmonary anastomosis demonstrated significantly increased
microvessel density compared with control subjects (32.7 ± 2.8 vs 9.3 ± 4.6,
P = .02, and 31.5 ± 15.7 vs 9.3 ± 4.6, P = .01, respectively). There was no
difference in microvessel density in children with and without clinically
apparent pulmonary arteriovenous malformations after cavopulmonary anas-
tomosis (P = .9). The children with pulmonary arteriovenous malformations
had numerous greatly dilated vessels that were absent in the asymptomatic
children after cavopulmonary anastomosis.
Conclusions: After cavopulmonary anastomosis, pulmonary microvessel
density is increased even in the absence of clinically apparent pulmonary
arteriovenous malformations, supporting the presence of a constant angio-
genic stimulus. Children with clinically apparent pulmonary arteriovenous
malformations possess large numbers of greatly dilated pulmonary
microvessels, which are absent in asymptomatic children after cavopul-
monary anastomosis. These results suggest that the transition to clinically
apparent pulmonary arteriovenous malformations may be due to mecha-
nisms that lead to vessel dilation and remodeling. (J Thorac Cardiovasc Surg
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ence of a constant angiogenic stimulus, asymptomatic
patients should also demonstrate evidence of increased
blood vessel proliferation in the lungs after cavopul-
monary anastomosis. Support for this theory comes from
contrast echocardiographic studies that have demonstrat-
ed increased right-to-left shunting in patients without
clinical evidence of PAVMs who have undergone
cavopulmonary anastomosis.5,6 This shunting can be
demonstrated within weeks after cavopulmonary anasto-
mosis and presumably is due to early vascular prolifera-
tion that occurs in the lungs of these children.
Microvessel density (MVD) has been used extensive-
ly in oncologic studies as a marker of angiogenesis.7-9
In the present study, we determined the MVD in the
lungs of children after cavopulmonary anastomosis
who did not have clinical evidence of PAVMs. We com-
pared this with the MVD in patients with clinically
apparent PAVMs after cavopulmonary anastomosis and
with the MVD of normal control subjects. Increased
MVD in asymptomatic patients after cavopulmonary
anastomosis would suggest the presence of a constant
angiogenic stimulus in the lungs of these children
despite the lack of clinically apparent PAVMs.
Methods
Patient and control specimens. After obtaining informed
consent, we took lung biopsy specimens from 8 patients after
cavopulmonary anastomosis at the time of the Fontan proce-
dure. Three of these patients had angiographically document-
ed PAVMs, and the other 5 had no clinical or angiographic
evidence of PAVMs. Peripheral lung biopsy specimens were
obtained from either the lingula of the left lung or the middle
lobe of the right lung with the lung fully inflated with tempo-
rary inspiratory hold from the ventilator. Control lung speci-
mens from 4 children with neither congenital heart disease
nor significant lung disease were obtained from archived
pathology specimens. These control specimens included 2
lung biopsy specimens—the first from a child with an acute
viral illness and the second from a child with systemic lupus
erythematosus. The other 2 specimens were from autopsies—
the first from a child who died of acute viral myocarditis and
the other from a child who died of rabies encephalitis. The
study was approved by the institutional review board of
Children’s Hospital and Regional Medical Center, Seattle,
Washington.
Histology and immunohistochemistry. All surgical and
autopsy specimens were immediately fixed in formalin and
then embedded in paraffin. Sections 5-µm thick were cut,
deparaffinized in xylene, and rehydrated in graded alcohols.
Sections were stained for routine histologic evaluation with
hematoxylin and eosin and Movat pentachrome. For immuno-
histochemical staining, endogenous peroxidase was quenched
with 3% hydrogen peroxide for 10 minutes. Sections were
steamed in citrate buffer (pH 6.0) for 20 minutes to improve
antigen retrieval. After cooling for 20 minutes at room temper-
ature, sections were washed in phosphate-buffered saline solu-
tion (PBS, pH 7.4). Rabbit anti-human primary antibody
against the endothelial marker, von Willebrand factor (DAKO
Corporation, Carpinteria, Calif), diluted 1:500 in 1% bovine
serum albumin (BSA) in PBS, was applied to sections.
Sections were incubated at room temperature for 60 minutes in
a humidity chamber. After being washed in PBS, biotinylated
goat anti-rabbit secondary antibody (Vector Laboratories,
Burlingame, Calif) diluted 1:500 in 1% BSA/PBS was applied.
Sections were incubated at room temperature for 30 minutes.
After the sections were washed in PBS, avidin-biotin enzyme
complex was added (Vector Laboratories) and slides were
incubated at room temperature for 30 minutes. The sections
were developed with diaminobenzidine tetrahydrochloride
(Sigma Chemical Co, St Louis, Mo) and counterstained in
methyl green. Sections incubated with 1% BSA in PBS in
place of the primary antibody served as negative controls.
Microvessels staining positively for von Willebrand factor
were counted in 10 high-power fields (200×) by 2 investiga-
tors. Results for 2 of the 3 patients with clinically apparent
PAVMs have been published previously.4
Statistical analysis. Statistical analysis was carried out
with SAS statistical software, version 6.12 (SAS Institute, Inc,
Cary, NC). Analysis of variance was used to compare MVD
among patients with and without PAVMs after cavopulmonary
anastomosis, as well as control subjects. The Student t test was
used to compare ages of patients after cavopulmonary anasto-
mosis and controls. Results are expressed as the mean ± the
standard deviation.
Table I. Demographics of patients after cavopulmonary anastomosis
Patient No. Clinically Oxygen Time interval since
(age [y], sex) evident PAVMs saturation (%) Diagnosis Glenn shunt (y)
1 (3.0, F) Yes 83 Heterotaxy 2.2
2 (12.0, M) Yes 65 Heterotaxy 7.0
3 (7.9, M) Yes 71 Transposition, double-inlet left ventricle 6.6
4 (1.9, M) No 85 Tricuspid atresia 1.3
5 (2.9, M) No 84 Pulmonary atresia 1.7
6 (3.4, F) No 84 Pulmonary atresia 1.8
7 (3.9, F) No 80 Tricuspid atresia 3.5
8 (1.8, F) No 85 Hypoplastic left heart syndrome 1.4




Table I shows the demographics of the patients after
cavopulmonary anastomosis. There was no statistically
significant difference in the ages of patients and con-
trols (4.6 ± 3.5 years vs 5.8 ± 6.3 years; P = .7). Fig 1
illustrates staining with Movat pentachrome and von
Willebrand factor in 1 patient with symptomatic
PAVMs after cavopulmonary anastomosis, in 1 patient
without clinically evident PAVMs after cavopulmonary
anastomosis, and in 1 control patient. After cavopul-
monary anastomosis, both symptomatic and asympto-
matic patients had a much higher number of pulmonary
microvessels than did control subjects. The control
specimens showed no significant abnormalities on
microscopic examination; specifically, 1 specimen was
completely normal, 2 showed minor focal inflamma-
tion, and 1 showed minor focal fibrosis.
After cavopulmonary anastomosis, patients with and
without clinical evidence of PAVMs demonstrated sig-
nificantly increased MVD compared with control sub-
jects (32.7 ± 2.8 vs 9.3 ± 4.6, P = .02, and 31.5 ± 15.7
vs 9.3 ± 4.6, P = .01, respectively). There was no dif-
Fig 1. Staining for Movat pentachrome and von Willebrand factor in a patient with a cavopulmonary anastomosis with
angiographically documented PAVMs (A and D), a patient without clinical or angiographic evidence of PAVMs after
cavopulmonary anastomosis (B and E), and a control patient (C and F) (original magnification 200×). Arrows demon-
strate vessels staining positively for von Willebrand factor (D, E, and F). Large dilated “lakes” (arrows) are present only
in the Movat-stained sections from a patient with symptomatic PAVMs (A).
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ference in MVD in children with and without clinical-
ly apparent PAVMs after cavopulmonary anastomosis
(P = .9) (Fig 2).
Routine histologic sections stained with hematoxylin
and eosin or Movat pentachrome demonstrated a sig-
nificant qualitative difference between patients who
had symptomatic PAVMs after cavopulmonary anasto-
mosis and patients who did not (Fig 1). Sections from
the 3 patients with symptomatic PAVMs stained with
Movat pentachrome demonstrated numerous greatly
dilated vessels, as well as chains of smaller vessels.
These chains of numerous small vessels were also pre-
sent in asymptomatic patients after cavopulmonary
anastomosis; however, the large dilated vessels were
not present in these patients.
Discussion
Abnormal angiogenesis is an etiologic factor for
numerous medical conditions including tumor metasta-
sis, diabetic retinopathy, rheumatoid arthritis, and gas-
tric ulceration.10 PAVMs developing after cavopul-
monary anastomosis may also represent a form of
abnormal angiogenesis. We undertook the present
study to determine whether a sensitive indicator of
angiogenesis (MVD) could be used to demonstrate
blood vessel proliferation in the lungs of children early
after cavopulmonary anastomosis before the develop-
ment of clinically apparent PAVMs. MVD determined
by von Willebrand factor staining has been used exten-
sively as a technique to determine the angiogenic
potential of tumors from a wide variety of tissues
including breast, colon, and lung.7-9
This approach was chosen to provide a histologic
correlate to echocardiographic studies that have
demonstrated subclinical PAVMs in asymptomatic
children after cavopulmonary anastomosis. In these
studies, microbubble contrast echocardiography
demonstrated right-to-left shunting in children with-
out symptomatic PAVMs as early as 6 weeks after
cavopulmonary anastomosis.5,6 Our results corrobo-
rate these echocardiographic studies, demonstrating
increased MVD in patients after cavopulmonary
anastomosis. Five of these patients had no angio-
graphic or clinical evidence of PAVMs but clearly
had evidence of increased pulmonary vascularity at a
microscopic level. In fact, MVD in these asympto-
matic patients was similar to that in patients with
clinically apparent PAVMs. These increased numbers
of small vessels presumably represent the histologic
correlate of the right-to-left shunt demonstrated by
contrast echocardiography.
We4 have previously described the histologic features
of lung tissue from children with clinically apparent
PAVMs after cavopulmonary anastomosis. The pre-
dominant histologic feature appeared to be large num-
bers of blood vessels extending far into the periphery of
the pulmonary parenchyma. We described 2 different
morphologic types of vessels in these patients—clus-
ters of multiple small blood vessels (“chains”) and
large, dilated, highly branching vessels (“lakes”).
Despite increased MVD in the 5 asymptomatic patients
in the present study due to an abundance of vessels
with “chains” morphology, none of these patients had
the large dilated “lakes” that we found in children with
clinically symptomatic PAVMs. The absence of vascu-
lar “lakes” in these children probably accounts for their
angiographically normal appearance.
The development of dilated, thin-walled vessels
appears to represent the histologic transition between
the absence of symptoms and clinically apparent
PAVMs in children who have had cavopulmonary anas-
tomosis. More important, this finding implies a change
in molecular mechanisms that control vascular growth
and morphology in this condition. Both groups demon-
Fig 2. Mean MVD per high-power field (200×) in patients
after cavopulmonary anastomosis with clinically evident
PAVMs, without clinical evidence of PAVMs
(Asymptomatic Post-CPA), and controls. Error bars repre-
sent standard deviation.
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strate evidence of a constant angiogenic stimulus
resulting in a quantitative increase in blood vessel num-
ber compared with controls. However, patients with
clinically apparent PAVMs have a further qualitative
difference in vessel morphology from “chains” alone to
one in which “lakes” are prevalent.
Potential control mechanisms for this histologic tran-
sition would have to account for vascular dilation and
wall thinning in addition to vascular proliferation. We
speculate that the transition of molecular control for
these events involves a change from predominant vascu-
lar proliferation in asymptomatic patients after cavopul-
monary anastomosis to mechanisms in which vascular
remodeling predominates in children with PAVMs. This
molecular switch to predominant vascular remodeling
represents a fruitful area of future investigation into this
condition and a current focus of our laboratory.
The pattern of development of PAVMs in children
who have had cavopulmonary anastomosis suggests
that the liver may play an important role. PAVMs form
in the ipsilateral lung after a classic Glenn shunt11 and
bilaterally after a bidirectional Glenn shunt or
Kawashima procedure.3 In each of these instances,
PAVMs develop in the pulmonary circulation that is
devoid of hepatic venous effluent. Reconstitution of
hepatic venous drainage to the lungs results in regres-
sion of PAVMs.2,12
Further evidence for the role of the liver in this phe-
nomenon comes from the observation that a similar
clinical picture is seen in some patients with liver fail-
ure who have progressive cyanosis from intrapul-
monary shunting. This phenomenon, termed the
hepatopulmonary syndrome, closely resembles the
angiographic and histologic picture of PAVMs occur-
ring after cavopulmonary anastomosis and resolves
after liver transplantation.3,13,14 These clinical observa-
tions support the hypothesis that PAVMs occurring
after cavopulmonary anastomosis may represent new
blood vessel growth due to lack of a hepatic inhibitor
of angiogenesis. We1 have partially purified a factor
from the conditioned media of cultured hepatocytes
that inhibits endothelial cell proliferation. The present
study does not directly address the role of the liver in
the development of PAVMs after cavopulmonary anas-
tomosis. Absence of a liver factor may be the cause of
this presumed vascular proliferation that all children
demonstrate after cavopulmonary anastomosis, as well
as influencing the vascular remodeling that leads to
clinically apparent PAVMs.
On the basis of our previous work suggesting that
these lesions are due to abnormal angiogenesis under
hepatic control, we have interpreted that vascular pro-
liferation plays a role in the development of these
lesions, at least early in the course of their develop-
ment. However, an alternative theory is that these
abnormal blood vessels seen in children after
cavopulmonary anastomosis are actually dilated col-
laterals that form from embryonic vascular channels
already present in the lung.15 We4 have previously
shown that clinically apparent PAVMs are negative
for proliferating cell nuclear antigen, a marker of vas-
cular proliferation. This result suggests that at the lat-
est stage of PAVM development, these lesions are no
longer highly proliferative, which further underlines
the importance of vascular remodeling and dilatation
in the etiology of these lesions. We are currently
studying lung tissue from children with early (asymp-
tomatic) and late (clinically apparent) PAVMs using
protein and mRNA techniques for markers of angio-
genesis and vascular remodeling. Ideally, these stud-
ies will further define the exact contribution of these
processes to the development of these lesions.
A limitation of the present study is the small number
of patients examined. However, increased MVD was a
constant finding in all of the patients who were exam-
ined after cavopulmonary anastomosis. MVD in all of
these patients exceeded that in any of the control sub-
jects. In addition, the fact that these biopsy specimens
were obtained from peripheral pulmonary parenchyma
confirms the diffuse nature of this process, which may
be even more advanced centrally in the lung. Another
limitation of the study is the lack of completely normal
controls; however, all control patients had an acute
onset of illness of less than 1 week in duration before
biopsy or autopsy and demonstrated essentially normal
pulmonary architecture. A further limitation exists in
failing to control for hypoxia, which itself is a potent
stimulator of angiogenesis and which was present in all
of the patients after cavopulmonary anastomosis.
Further studies determining MVD in lung tissue from
hypoxic children who have not undergone cavopul-
monary anastomosis or animal models might help to
address this concern.
Summary
The development of PAVMs may represent an abnor-
mal form of angiogenesis under hepatic control, which
has led us to hypothesize that asymptomatic patients
should have subclinical manifestations of angiogenesis
after cavopulmonary anastomosis. Our results suggest
that a constant angiogenic stimulus is present after
cavopulmonary anastomosis, with asymptomatic
patients demonstrating 3-fold higher MVD than control
subjects. A comparison of the histologic features
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between asymptomatic patients and children with
PAVMs after cavopulmonary anastomosis demon-
strates a histologic transition to the development of
dilated thin-walled vessels extending into the lung
periphery. Identifying mechanisms that control vascu-
lar remodeling in this lesion, as well as those that con-
trol vascular proliferation, will be important to the ulti-
mate understanding of its etiology.
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Discussion 
Dr Richard A. Jonas (Boston, Mass). When Dr Duncan
was with us at Children’s Hospital in Boston, he and I had the
exciting opportunity to collaborate with the godfather of
angiogenesis, Dr Judah Folkman. Working in conjunction
with one of the surgical residents in Dr Folkman’s laboratory,
Dr Blair Marshall, we were well on the way to purifying a
hepatic-derived angiogenic inhibitory factor in an animal
model. I am delighted to see that Dr Duncan has continued
his interest in this area in Seattle and is presently undertaking
both laboratory and clinical studies, as Dr Starnes has
described. 
The main finding of this report is a very important one,
namely, that it appears that any child who undergoes cavopul-
monary anastomosis is susceptible to a process of vascular
proliferation and must ultimately be at risk for the develop-
ment of symptomatic PAVMs resulting in important cyanosis.
Thus, it would seem likely that a philosophy of eventually
converting all patients who have had a bidirectional Glenn
shunt to a Fontan-type circulation is justified. 
Can you speculate on why some patients seem to be pre-
disposed to the rapid development of symptomatic PAVMs?
For example, the patient with heterotaxy after a Kawashima-
type procedure appears particularly susceptible to accelerated
development of clinically important PAVMs. What is it about
this population or other individual patients with accelerated
development of PAVMs that distinguishes them from patients
who have only slow progression of cyanosis? 
Second, how are you presently studying this problem in a
laboratory model? In Boston we were using a cell culture
model with bovine endothelial cells stimulated by a hepatic
factor derived from rat liver. Do you have a large animal
model and can you share any preliminary information with us
regarding the link between a hepatic-derived factor and pro-
liferation of pulmonary blood vessels? 
Dr Starnes. Thank you, Dr Jonas, for those comments. 
The development of PAVMs is certainly a complicated
process, and we believe that a liver factor is probably the major
factor; however, undoubtedly multiple other factors are
involved. One example is cyanosis itself. Hypoxia is a known
stimulus for angiogenesis. In fact, we recently reported that
patients with cyanotic congenital heart disease have elevated
levels of vascular endothelial growth factor, a very potent angio-
genic stimulus, in their serum. Thus, the degree of cyanosis may
be one factor that is more important in some children.
In patients with heterotaxy, the difference in pressure
between the caval system and the splanchnic venous system
may be an additional factor that is important in the rapid pro-
gression of PAVMs. 
Regarding the second question, we agree that an animal
model is of the utmost importance in determining the mecha-
nisms involved in this process. First, an animal model would
allow us to have essentially limitless amounts of tissue to study.
Another reason is that we could study the progression of these
lesions over a long period. However, most important, the use of
an animal model would allow us to develop some medical ther-
apies for this problem. A growing number of antiangiogenic
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agents are available, such as interferon-α or inhibitors of vascu-
lar endothelial growth factor, that we could use in an animal
model to see whether we can induce these lesions to regress. 
For these reasons, we have developed a small animal model
of PAVMs after cavopulmonary anastomosis in a rat. This
model successfully reproduces the condition seen in human
beings. Angiographic evidence of PAVMs occurs 12 months
after cavopulmonary anastomosis in this model, whereas at
earlier time points the angiograms were normal. However,
using the same methods described in this report, we found
evidence of vascular proliferation in this animal model as
early as 2 months after surgery. 
We chose a small animal model instead of a large animal
model for a couple of reasons. First is the expense. We can
study a larger number of rats than we can larger animals.
The second reason is the availability of agents for the mol-
ecular analysis. These agents are widely available in a rat
model. 
Regarding the third question, the identification of this
hepatic factor was started at Boston Children’s with Dr
Folkman, and we are very fortunate to have that as our back-
ground. Over the past couple of years in Seattle, we have
focused on our animal model and these studies in human tis-
sue, but in the near future we will be focusing on the hepatic-
derived factor again to see whether we can further purify and
finally identify this factor. The recent development of immor-
talized hepatic cell lines would make this much easier to do
today than it was even a few years ago. 
